

**First
day**

6th Annual Multidisciplinary Uro-oncology Congress 2024

Espinas Palace Hotel, (19-21 September 2024)- (29-31 Shahrivar 1403)

“Scientific Programme”

Thursday – 29 Shahrivar, 1403)19 September, 2024) -(Tehran GMT+3:30)



(Morning) (Palace Hall)

Official Opening			
8:00 -8:15	Quran Recitation, National Anthem, Inauguration		
Chairmen: Gh.Pourmand,M.A.Zargar ,F.Samiee, H.Mombeini,H.Mazdak			
08:15-10:30 Session I: Prostate Cancer			
Hall manager: J.Koochi.MD Management of High risk localized locally advanced Prostate Cancer Treatment for biochemical recurrence/PSA persistence	Time 08:15-8:30	Is DRE for definition of local T-stage still appropriate in the time MRI and next-generation imaging? • What's your opinion AI?	S.Ebrahimi.MD
	Debate: Sh.Zeighami.MD 08:30-9:00	How to best manage a fit patient with high-risk localized and locally advanced prostate cancer? (Multimodality approach) 1.Surgery as radical local treatment. 2.Radiation therapy as radical local treatment. • What's your opinion AI?	H.Niroomand.MD H.Molana.MD
	Panel discussion: Moderator: 9:00-10:00 H.R.Ghorbani	<ul style="list-style-type: none"> • Case Presentation • How to manage patients with PSA persistence following radical prostatectomy? • How to select patients with BCR in whom salvage radiation therapy can be postponed? • Which patients with high-risk first BCR after radical prostatectomy are candidates for systemic therapy alone without local salvage RT? • In patients with BCR and positive lesion(s) in the Opportunistic Prostate Cancer Screening with Biparametric MRI (VISIONING) pelvis – stereotactic or whole pelvis RT? • Opportunistic Prostate Cancer Screening With Biparametric MRI(VISIONING) 	H.R.Ghorbani.MD N.Naghdi.MD R.Jafari.MD N.Musavi.MD R.Ghaletaki.MD
	10:00-10:15		S.A.Momeni.MD
	10:15-10:30	Satellite Symposium(Behestan Darou): Frontline therapy With Enzalutamide	M.Ayati.MD M.R.Nowroozi.MD E.Amini.MD S.A.Momeni.MD
Hall manager: Sh. Hejazi.MD		Chairmen: E.Amini, A.Zare, F.Gitnavard, M.Ghafouri, M.Dadpour,	
Time 08:30-10:00 Parsa Hall		Uro-Oncology Research Center Residency Competition	
10:30-10:40	Opening Ceremony	Congress President: M.Ayati.MD President of the research Center: M.R.Nowroozi.MD Congress scientific secretary: S.A.Momeni,MD	
10:40-11:15 Break & Visit Exhibition			
Thursday, 11:30-13:00 Industry Session, Parsa Hall			
11:30-12:00	N.Masror	Introduction to Papilloguard and Fluguard Vaccines: A Review of Studies Conducted on These Vaccines	Orchidpharmed
12:00-12:30	A.Mozaffari	How can to help maintion a healthy prostate	Daryan Salamat
12:30-13:00	F.Khaghazchi	PSMA PET CT in initialan staging of prostate Cancer	PET Scan Khatam

6th Annual Multidisciplinary Uro-oncology Congress 2024

Chairmen: A.Mehrsai, H.Rajaei, A.Shamsa, S.Hazhir, M.Jamali, A.Javaherforoshzadeh

Time 11:15-13:15

Session II: Prostate Cancer

Localized Prostate cancer Moderator: M.R.Nowroozi.MD	<ul style="list-style-type: none"> • (Case presentation) • MRI-targeted or Standard Biopsy for Diagnosis • Defining Risk and Optimal Patient Selection • Use of MRI and PSMA PET for Active Surveillance Patients' Trust in Artificial Intelligence-based Decision-making for Localized Prostate Cancer 	S.Montazeri.MD A.R.Farzin.MD N.Masoumi.MD M.Safavi.MD
---	---	--

12:30-13:15	Thematic Session	
Management of metastatic hormone-sensitive prostate cancer (mHSPC) Moderator: K.Kamali.MD	<ul style="list-style-type: none"> • Ideal monitoring of patients with mHSPC – what are relevant prognostic/predictive factors for management of patients? • In which patients with synchronous & metachronous low-volume mHSPC do you recommend “total therapy”? • De-escalate treatment in selected patients with mHSPC? • Role of Lu-177PSMA radioligand therapy. 	A.Jenabian.MD B.Mofid.MD M. Aghili.MD M.Abbasi.MD

13:15-14:15	Pray & Launch	
-------------	---------------	--

Chairmen: N.Simforoosh, H.Shahrokh, M.Sedehi, A.Hamidimadani, M.Yazdani, A.Akbarzadehpasha

Time 14:15-15:45

Session III: Prostate Cancer, Testis cancer

Hall manager: M.Rostami.MD	MDT discussion on daily cases Moderator: A.Razi.MD 14:15-14:45	Enlarged prostate, rising PSA with negative prostate biopsies: What's next? <ul style="list-style-type: none"> • Case presenter • Discussants • What's your opinion AI? • Take-home messages 	F.Allameh.MD M.Soleimani.MD A.Asadollahpour.MD M.Kardoost.MD A.Razi.MD
	Navigating the landscape: Testicular tumor across stages. Moderator: A.Moradi.MD 14:45-15:45	<ul style="list-style-type: none"> • MRI in the diagnosis of indeterminate testicular lesions- a game changer? • Adjuvant Therapy in Stage I Testicular Cancer: Surveillance for All • Primary retroperitoneal lymph node dissection in marker positive testicular cancer • New definition of the “Growing teratoma syndrome” based on molecular subtyping and novel biomarkers 	A.Abrishami.MD A.Majidnezhad.MD E.Moudi.MD

Chairmen: S.Sahebkhaf, H.R.Gholamrezaei, R.Mahdavi, S.R.Taghavi, M.K.Kazemeini

Time 15:45-16:00	Sentinel lymph-node staging in testicular cancer patients.	M.Jamshidi.MD
16:00-17:00 Incidental testicular mass detected in infertility work-up Moderator: S.Salehi.MD	<ul style="list-style-type: none"> • Case presentation • Radical orchidectomy • Partial orchidectomy • Monitor • Discussion 	M.Alemi.MD A.Arbab.MD Sh.Rezazadeh.MD D.Khazayeli.MD S.Salehi.MD

15:00-17:00 Oral Presentation Chairmen: L. Sharifi, S.Ohadian, F.Radmanesh, A.Tavosian, H.Dialame (Parsa Hall)

Friday –30 Shahrivar,1403) 20 September, 2024) (Palace Hall)

Time 08:15-10:30 Session I: Bladder Cancer and Upper tract TCC

Hall manager: A.H.Khazzaei.MD Bladder Tumors	08:15-08:30	Modern bladder preservation strategy • What's your opinion AI?	E.Amini.MD
	Debate: 08:30-09:00 Moderator: K.Hassanzadeh .MD	Controversies in initial staging for bladder cancer? Debater 1:No need for TURBT, Vi-RADS makes the diagnosis Debater 2: TURBT is mandatory before any treatment • What's your opinion AI?	F.Valizadeh.MD A.Ariaifar.MD
Debate: 09:00-09:30 Moderator: A.Basiri.MD		Healthy Patient with TIHG Micropapillary NMIBC - What is the best treatment option? What if mixed histologic subtypes in addition to micropapillary? Debater 1: Intravesical therapy best option Debater 2: Upfront radical cystectomy is best. • What's your opinion AI?	A.R.Farzin.MD F.Khaleghimehr.MD
Debate: 09:30-10:00 Moderator: H.Izadpanahi.MD		Patient with non-invasive, high-grade upper tract disease in setting of prior radical cystectomy – what is optimal management? What if GFR ~ 50 instead of 80? Debater 1: Conservative management should be offered Debater 2 : Nephroureterectomy is needed • What's your opinion AI?	S.H.Inanloo.MD M.Sarkarian.MD
10:00-10:30 Moderator: H.Jamshidian.MD		How do we manage a patient with frequent recurrence of LG papillary tumors in the bladder despite intravesical chemotherapy and BCG therapy? Debater 1: Repeated TUR +/- chemo is necessary Debater 2 : Time to do surveillance/de-escalate therapy • What's your opinion AI?	A.Tehranchi.MD M.Sadri.MD
Hall manager: A.H.Moradabadi.MD	Chairmen: E.Amini, A.Zare,F. Gitinavard, M.Ghafouri, M.Dadpour, B.Shakiba, M. Haddad		
Time 08:30-10:00 Parsa Hall	Uro-Oncology Research Center Residency Competition		
10:30-11:00	Break & Visit Exhibition		
Friday, 11:00-12:00 Industry Session, Parsa Hall			
11:00-11:30	H.Ghorbani	Zoladex in management of prostate cancer	Astrazeneca
11:30-12:00	A.Hamidi madani	Hormonal Therapy in Prostate Cancer	Homa Pharmed
Chairmen: M.Sanadzadeh,S.Y.Hosseini,M.R.Darabi,A.Nooralizadeh,H.Abbasi			
Session II: Management of Bladder neck stenosis, erectile dysfunction, urinary incontinence			
Time 11:00-12:00 Moderator: S.J.Hosseini.MD		• Management of Impotency after Radical prostatectomy • Management of urinary incontinence after RP • Management of postprostatectomy anastomosis stenosis	H. Salimi.MD M.Hosseini.MD R. Sharifian.MD
12:00-13:00	Acknowledgement		• Mentors in Uro-oncology. • Industry Partners • Taking memorable group photo.
13:00-14:30	Pray & Launch		

6th Annual Multidisciplinary Uro-oncology Congress 2024

Chairmen: A.Kajbafzadeh, B.Ghazimoghadam, I.Khosropanah, N.Shaksasalim, M.Taheri, M.A.Amirzargar

Time 14:30-16:45 Session III: Kidney Cancer

Hall manager: A.Abbasi.MD Contemporary Management of metastatic Kidney Cancer: Moderator: A.Tabibi.MD 14:30-15:30	<ul style="list-style-type: none"> Cases and Discussion Risk Stratification and Managing the Primary Role of Cyoreductive Nephrectomy in IO Era Where Dose SBRT Fit in? role in primary renal tumor Best Systemic Therapy 	S.R.Yahyazadeh.MD R.K.Nayeri.MD F.Farhan.MD A.Mafi.MD
15:30-15:45 Lecture	<ul style="list-style-type: none"> Fertility Preservation in Male Urological Cancer 	A.Kheradmand.MD
15:45-16:45 Panel: Moderator: H.Arshadi.MD	<ul style="list-style-type: none"> Wilm's Tumor Paratesticular Rhabdomyosarcoma Role of PET-CT scan 	S M.Ghohestani.MD P.Hekmati.MD H.Amirzargar.MD Gh.Divband.MD

Third day

Saturday –31 Shahrivar, 1403) 21 September, 2024)
(Palace Hall)

Chairmen: S.K.Aghamir, H.R.Mirzaee, R.Maghsoudi, H.Rokni, S.Kaghazchi

Time 08:15-10:00 Session I: Kidney tumors and sarcoma

Hall manager: A.M.Nadafi.MD	08:15-9:15 Management of Angiomyolipoma A.Nikfallah.MD	<ul style="list-style-type: none"> Clinical manifestations and Histologic variants Role of Imaging Role of SAE and TA Role of Surgery Role of medical treatment Role of Active surveillance and follow up 	M.R.Ensafdaran.MD M.Ghafoori.MD H.Rokni.MD H.Radfar.MD M.R.Soltani.MD M.J.Rajabi.MD
	09:15-10:00 Sarcoma in GU MDT Case-based discussion Moderator: M.Ayati.MD	<ul style="list-style-type: none"> Sarcoma of kidney Sarcoma of bladder Role of radiation therapy Role of PET-CT scan 	M.Shiraghayi.MD F.Ghaderpanah.MD P.Adeli.MD S.Farzanefar.MD

10:00-10:30

Break & Visit Exhibition

10:30-10:45

Keynote Speaker
Screening For Urinary Bladder Cancer By Liquid Biopsy Golestan Cohort Study

R. Malekzadeh.MD

Chairmen: M.Ayati , M.A.Zare, Gh.Mohseni, A.Ghalamkari, H.Ahmadnia

Session II: Forensic Medicine in Urology

Time
10:45-12:00

A.M.Ziaee, A.Yarmohammadi, M.R.Nikoobakht, M.R.Kheradmand, H.Mousavi Bahar

Forensic Medicine in Urology. Moderator:
M.R.Nowroozi.MD